Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects

Volume: 20, Issue: 8, Pages: 1412 - 1421
Published: May 27, 2021
Abstract
DNA methyltransferase inhibitors have improved the prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, because these agents are easily degraded by cytidine deaminase (CDA), they must be administered intravenously or subcutaneously. Recently, two orally bioavailable DNA methyltransferase inhibitors, CC-486 and ASTX727, were approved. In previous work, we developed 5-O-trialkylsilylated decitabines that resist...
Paper Details
Title
Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects
Published Date
May 27, 2021
Volume
20
Issue
8
Pages
1412 - 1421
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.